AlphAIalphai — Financial news for AI agents
BenzingaNOV 193 min read$CRMD

Cormedix Director Trades $342K In Company Stock - Cormedix (NASDAQ:CRMD)

Janet Dillione, Director at Cormedix ( NASDAQ:CRMD ) , reported an insider sell on November 19, according to a new SEC filing. What Happened: Dillione's recent Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday unveiled the sale of 30,000 shares of Cormedix.

Original reporting
Benzinga · Benzinga Insights
Published Nov 19, 2025, 3:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 20, 2025, 12:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Cormedix Director Trades $342K In Company Stock - Cormedix (NASDAQ:CRMD) — source image
Source · www.benzinga.com
Decision brief

The 30-second read

$CRMDNeutralLow
01

Why it matters

The insider sale suggests cautious sentiment but is not conclusive of future performance; investors should consider additional factors.

02

Market read

The insider transaction has limited immediate impact but warrants monitoring for potential trend indications.

03

What to watch

Recent clinical trial results, upcoming catalysts, or broader market trends could offset the negative signal from insider sales.

Timing: short-term (within 1-2 weeks)

Background

Janet Dillione, a director at Cormedix, sold 30,000 shares valued at approximately $342,000, as per SEC filings.

Company-level read

Ticker impact

$CRMDNeutralMedium confidence
Context

The insider sell by director Janet Dillione of Cormedix (NASDAQ:CRMD) indicates potential insider sentiment shift.

Expected impact

Moderate negative impact expected in the short term, approximately 3-5% decline potential.

Evidence & confidence

While insider sales can signal caution, they do not necessarily indicate a decline in fundamentals. The sale amount is significant but not extraordinary, and other factors should be considered.

Market effects

Sector

The sale may reflect broader concerns within the Life Sciences sector, but no immediate sector-wide impact is evident.

Regional

Limited regional impact; news pertains to US-based insider activity.

Global

Negligible; specific to company insider activity without broader global implications.

Counterpoint

What could challenge this read

Insider selling may be due to personal liquidity needs and not indicative of company fundamentals; the stock could rebound if fundamentals remain strong.

Key entities

  • Person
    Janet Dillione

    Director at Cormedix involved in the recent stock sale.

  • Company
    Cormedix

    Biotech firm listed on NASDAQ, involved in life sciences.

Read at source← All news

Related articles

AUG 14
$CRMDMed

CorMedix Q2 Earnings Call Highlights

CorMedix (NASDAQ:CRMD) reported Q2 revenue rising to $39.7M from $39.7M a year earlier, with 2026 including $66.1M DefenCath sales and $35.8M from the Melinta portfolio. Net income was $26.0M ($0.33 basic). It reaffirmed 2026 revenue guidance of $325M-$345M and raised adjusted EBITDA to $125M-$140M. REZZAYO supplemental NDA is planned for Q3 2026, with FDA action expected H1 2027.

yahoo.com6 min
AUG 13
$CRMDMedAI 8/10

CorMedix, Inc.: Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

CorMedix Therapeutics (Nasdaq: CRMD) reported Q2 2026 consolidated revenue of $101.9M, including $66.1M DefenCath sales and $35.8M from the Melinta portfolio. Net income was $26.0M and adjusted EBITDA $58.7M. The company maintained FY2026 revenue guidance at $325M-$345M and raised adjusted EBITDA to $125M-$140M, with a REZZAYO sNDA FDA submission expected in Q3 2026.

finanznachrichten.de6 min
AUG 13
$CRMDHigh

CorMedix Inc. (CRMD): Results of Operations and Financial Condition

CorMedix Inc. (CRMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 crmd_q22026earningspr.htm EX-99.1 Document Exhibit 99.1 CORMEDIX THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ‒ Q2 2026 Consolidated Revenue of $101.9 million ‒ ‒ Q2 2026 Net Income of $26.0 million ; Adjusted EBITDA of $58.7 m

SEC EDGAR 8-K7 min
AUG 14
$UWMCMed

UWM sued for allegedly misleading investors on hedge strategy

Shareholder Doug Bond filed a class action against UWM Holdings in Michigan federal court, alleging securities fraud over disclosures about UWM’s interest rate derivatives hedge tied to its Two Harbors acquisition. The suit covers purchases from March 9 to Aug. 5, citing a $603.2 million derivatives loss and a $2.05 billion Oaktree cash infusion after a March revenue projection.

nationalmortgagenews.com4 min
AUG 14
$BAMedAI 8/10

Pentagon inks deals with Boeing, RTX to boost production of SM-3 components

The Pentagon signed seven-year framework agreements with Boeing and RTX to expand production of Standard Missile-3 components for SM-3 Block IB and Block IIA, including avionics and ejector assemblies Boeing supplies to Raytheon. The deals aim to stabilize supply chains and expand munitions output. Separately, the Missile Defense Agency awarded Raytheon a $745 million contract for Block IIA interceptors.

militarytimes.com5 min